Chemotherapy for Advanced Prostate Cancer
The primary modality of treatment for patients with disseminated cancer of the prostate fo-cusses on the suppression of androgenic stimulation of tumour growth. Androgen deprivation procedures of various kinds result in subjective/objective clinical benefits in the majority (70–80%) of patients with metastatic disease and, clearly, reflect some of the most effective systemic palliative treatments for solid tumours in man. Paradoxically however, the development of endocrine resistance, which is observed within a relatively predictable time frame, is an extraordinarily effective phenomenon. In prostate cancer, contrary to breast cancer, responses to second-line endocrine manipulations are uncommon, usually brief and subjective and, more important, have no impact on survival. Extensive data accumulated over the past few decades, derived from large-scale, prospective randomised trials testing various methods of androgen deprivation, have shown that the median time to progression and the median survival in cohorts of patients have consistently ranged from 12–18 months and 24–30 months, respectively [1,2]. These data also stress that the development of effective non-hormonal cytotoxic approaches is the key step in order to accomplish significant advances in the systemic treatment of this disease. Preclinical data have shown that various phenotypic changes are increasingly expressed in parallel with the development of endocrine resistance . These may represent either somatic mutations from a hor-monally sensitive to an insensitive state, expansion of previously insensitive cell clones, or, most likely, both .
KeywordsProstate Cancer Measurable Disease Endocrine Resistance Nitrogen Mustard Estramustine Phosphate
Unable to display preview. Download preview PDF.
- 8.Scher H, Yagoda A, Watson R, Serber M, Whitmore W: Phase II trial of adriamycin in bidimensionally measurable prostatic adenocarcinoma. J Urol 1984 (13):1099–1102Google Scholar
- 9.Torti F, Aston D, Lum BL, Kohler M, Williams R, Spaulding JT, Shortliffe LD, Freiha FS: Weekly doxorubicin in endocrine refractory carcinoma of the prostate. J Clin Oncol 1983 (1/8):477–482Google Scholar
- 10.Merrin C: Treatment of genitourinary tumors with cis-dichloro diamine platinum (II). Experience in 250 patients. Cancer Treat Rep 1979 (63):1578–1589Google Scholar
- 11.Rossof AH, Talley RW, Stephens R, Thigpen T, Samson M, Groppe C, Eyre HJ, Eisher R: Phase II evaluation of cis-dichloro diamine platinum (II) in advanced malignancies of the genitourinary and gynecological organs: A Southwest Oncology Group Study. Cancer Treat Rep 1979 (63):1557–1564PubMedGoogle Scholar
- 17.Isaacs JT: The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer.Google Scholar
- 19.Gibbons RP, Beckley S, Brady MF, Chu TM, Dekernion JB, Dhabuwala C, Gaeta FJ, Leoning SA, McKiel CR, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel IV, Schmidt JU, Scott WW, Slack NJ, Soloway MS, Murphy GP: The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate. J Surg Oncol 1983 (23):133–142PubMedCrossRefGoogle Scholar
- 20.Moore M: Chemohormonal therapy for stage D prostatic cancer. Preliminary results of a randomized trial. Am Soc Clin Oncol 1982 abstr C-461Google Scholar
- 21.Kedia KR, Kellermeyer RW: Hormonal stimulation followed by multiagent chemotherapy in advanced prostatic cancer. Cancer Chemoth Pharmacol 1982 (18):261–265Google Scholar
- 24.Seifter E, Bunn P, Cohen M, Ihde D: A trial of combination chemotherapy followed by therapy for previously untreated metastatic carcinoma of the prostate. J Clin Oncol 1984 (4):1305–1373Google Scholar
- 25.Eisenberger MA, Abrams JS: Chemotherapy for prostatic carcinoma. Sem Urol 1988 (6):303–310Google Scholar
- 26.Yagoda A: Response in prostate cancer: An enigma. Sem Urol 1984(1):311–319Google Scholar